Travere Therapeutics (NASDAQ:TVTX) reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its kidney ...
U.S. net product sales for the third quarter of 2026 were $220.2 million, compared to $113.2 million for the same period in ...
Travere Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported revenue was USD 224.56 million compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results